Nanopublications

@prefix this: <http://purl.org/np/RA2-dISS3g4AXlPLECdvCYWNM2vSt8CBR6UHbVdQrBTHw> .
@prefix sub: <http://purl.org/np/RA2-dISS3g4AXlPLECdvCYWNM2vSt8CBR6UHbVdQrBTHw#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix pav: <http://purl.org/pav/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix infores: <https://w3id.org/biolink/infores/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix umls: <http://identifiers.org/umls/> .
@prefix orcid: <https://orcid.org/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubInfo ;
    a np:Nanopublication .
}

sub:provenance {
  sub:assertion prov:generatedAtTime "2022-10-13T11:44:43.063138"^^xsd:dateTime ;
    prov:wasAttributedTo orcid:0000-0002-3668-2627 ;
    prov:wasQuotedFrom """ Nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. The largest and most consistent cardiovascular outcome benefit has been a reduction in stroke. There are no controlled trials demonstrating risk reduction with nebivolmolol tablets. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients.
""" .
  biolink: pav:version "2.3.0" .
}

sub:pubInfo {
  sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB" ;
    npx:hasSignature "DeWV0I6veD0Dp6gvPh4gydgzwVcK7RB1Q9R+C4yE/kTU5UhMp35X0RVMNOIDG/VAmOXbmr5E0hnvYAB1rhkuCrMyd2EBmWNUk8sBgz9nDIyRTMkttvbhG9bGR/9iFRbG8+1ByWq9kH1bTh8G+xXKzpLlrvWf7iW28/aWdyDPE99oObn7ikZrAWnAo5ytHTZ5PocnkWHKtcYYbR+y5Or7rdMQqU8xqVrM7QTpioJXyvC368XzMI+2kSCUtGN9DMSDD9yoWUK/Ef448T8pLK+Pd4nLrjR6dp+HKfsyGVq17lAAex5bU4X6nhfIfQkGCx1f0LbMdomL1KnHdIBERDj0fg==" ;
    npx:hasSignatureTarget this: .
  this: prov:generatedAtTime "2022-10-13T11:44:43.063138"^^xsd:dateTime ;
    prov:wasAttributedTo orcid:0000-0002-3668-2627 .
}